Decentralizing clinical trials: how COVID-19 has changed drug development

The COVID-19 pandemic brought an enormous urgency to the life sciences sector. Companies vied for suitable treatments and in less than a year, COVID-19 vaccines were developed. This demonstrated clearly that the sector could move at speed when necessary. Though vaccines were supported by regulators, inefficiencies in vaccine and drug development were exposed.

However, the pandemic created a huge problem for people running clinical trials, especially existing trials. Routine health care visits were discouraged or even banned. Everything moved to online consultations. How can you carry out clinical trial assessments if you can’t visit patients, and they can’t visit you? How did the industry speed up vaccine development?

To know more click here.

Let’s Get the Conversation Going

Leave your details below so we can help find the best solution for your organisation.









    Let’s Get the Conversation Going

    At MySASteam, we believe that every SMB deserves the Power to Know. Please leave your details below so we can find the best solution for your organisation. We’ll call you.